isogenica logo

Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on our proprietary fully synthetic antibody libraries and leveraging our CIS Display and Colibra™ technologies to accelerate the discovery.

Isogenica’s massive synthetic libraries are most optimally screened for antibody binders against soluble proteins or membrane targets (cell-based selections) using the company’s proprietary CIS Display platform.

Contact Isogenica via their website

News archive

20/05/2021   Isogenica announces Dr William (Bill) Eldridge promotion to Chief Scientific Officer...more

18/01/2021   Isogenica-Aro collaboration goes from strength to strength...more

08/12/2020   Isogenica Opens Pre-doc Program...more

30/11/2020   Isogenica publishes whitepaper on VHH in T cell redirection...more

30/11/2020   Isogenica supports MRC iCASE PhD Award...more

28/10/2020   Register for Isogenica's CAR-T webcast 25th November...more

02/06/2020   Meet Isogenica at PEGS Boston and BIO Digital...more

04/11/2019   Meet Isogenica at BIO-Europe and PEGS Summit Europe this month...more

15/10/2019   Dr Bjӧrn Cochlovius appointed to Isogenica’s Board of Directors...more

12/09/2019   Isogenica appoints Dr David Mead as Director of Business Development...more

12/08/2019   Isogenica joins the BioPartnership Programme

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code